Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- METI to Promote Industry, Government, Academia Alliance through BECON: Mr Okakura
May 7, 2001
- BUSINESS NEWS IN BRIEF -1-
May 7, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -2-
May 7, 2001
- BUSINESS NEWS IN BRIEF -2-
May 7, 2001
- Takeda Discovers Respiratory Disease-related Genes
May 7, 2001
- Only 2 out of 20 Keidanren Deregulation Proposals Implemented
May 7, 2001
- Short-acting Insulin Analog Treatment Effective in Type 2 Diabetes: JDA/Lilly Seminar
May 7, 2001
- 27 GEs Delisted 1 Year after Application of GE Rule
May 7, 2001
- Many Psychiatrists Dissatisfied with Drugs to Treat Schizophrenia
May 7, 2001
- CSTP Subpanel to Propose Promotion Strategy in Prioritized Fields
May 7, 2001
- OTC NEWS IN BRIEF
May 7, 2001
- PMSB Asks Manufacturers to Stop Supply of Phenacetin
May 7, 2001
- AstraZeneca's Diprivan Inj-Kit to Contribute to Preventing Accidents
May 7, 2001
- REGULATORY NEWS IN BRIEF
May 7, 2001
- Atorvastatin Raises Treatment Target Achievement Rates: Yamanouchi/Pfizer Seminar
May 7, 2001
- Japanese Global Strategy Update (1)
May 7, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF -1-
May 7, 2001
- Pricing Rule for Innovative Medical Devices to Be Studied
May 7, 2001
- Market Share of Generics Should Be Considered in Pricing of Long-listed Drugs: JMA
April 23, 2001
- LDP's Commission Lists 4 Points of Discussion for NHI Pricing Reform
April 23, 2001
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…